SEC Comment Letter 0000000000-23-006294 to Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc.
Date: June 12, 2023 · CIK: 0001860657 · Accession: 0000000000-23-006294
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272469
Letter
United States securities and exchange commission logo June 12, 2023 James G. Cullem Chief Executive Officer Allarity Therapeutics, Inc. 24 School Street, 2nd Floor Boston, MA 02108 Re:Allarity Therapeutics, Inc. Registration Statement on Form S-1 Filed June 7, 2023 File No. 333-272469 Dear James G. Cullem: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott E. Bartel, Esq.
Show Raw Text
United States securities and exchange commission logo
June 12, 2023
James G. Cullem
Chief Executive Officer
Allarity Therapeutics, Inc.
24 School Street, 2nd Floor
Boston, MA 02108
Re:Allarity Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 7, 2023
File No. 333-272469
Dear James G. Cullem:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Scott E. Bartel, Esq.